BioCardia: Funding, Investors & Team (Oct 2026)
We are a company that is in the advanced stages of developing therapies for cardiovascular diseases that have not been effectively addressed by current medical options. Our company, BioCardia, is focused on creating unique regenerative medicine solutions through our CardiAMP™ and CardiALLO™ therapies. The clinical results we have obtained for these treatments are strong and are based on the most rigorous data available, using marrow-derived cells delivered directly into the heart. In addition to these therapies, we have developed our Helix™ transendocardial delivery systems and Morph® vascular access products, which can also be utilized in other potentially successful regenerative medicine treatments. These products are partnered with other programs to maximize their effectiveness.
BioCardia has raised $9.3M across 3 funding rounds on record, the most recent an undisclosed round of $4.4M announced in Jun 2026.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioCardia Company Profile and Key Stats
Latest funding round on record: Jun 2026.
BioCardia Funding Rounds
BioCardia raised $3.6M in an undisclosed round announced in Dec 2022.
11 months later, an undisclosed round of $1.3M was announced in Nov 2023.
2.6 years later, an undisclosed round of $4.4M was announced in Jun 2026.
BioCardia Founders and Leadership Team
Contact details for the BioCardia team: 2 of 2 have an email address on file.
Start 14-day free trial →BioCardia Funding Compared to Other Biotechnology Startups
BioCardia's latest round of $4.4M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioCardia in Biotechnology and San Carlos
Companies Similar to BioCardia
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
BioCardia Funding FAQs
What does BioCardia do?
We are a company that is in the advanced stages of developing therapies for cardiovascular diseases that have not been effectively addressed by current medical options. Our company, BioCardia, is focused on creating unique regenerative medicine solutions through our CardiAMP™ and CardiALLO™ therapies. The clinical results we have obtained for these treatments are strong and are based on the most rigorous data available, using marrow-derived cells delivered directly into the heart. In addition to these therapies, we have developed our Helix™ transendocardial delivery systems and Morph® vascular access products, which can also be utilized in other potentially successful regenerative medicine treatments. These products are partnered with other programs to maximize their effectiveness.
How much funding has BioCardia raised?
BioCardia has raised $9.3M across 3 rounds on record. The most recent is an undisclosed round of $4.4M announced in Jun 2026.
When did BioCardia last raise funding?
BioCardia's most recent funding round on record is an undisclosed round of $4.4M, announced in Jun 2026.
Who founded BioCardia?
FundedIQ lists Peter Altman (Founder) at BioCardia.
Who is the CEO of BioCardia?
Peter A Altman is listed as CEO at BioCardia.
Where is BioCardia headquartered?
BioCardia is based in San Carlos, California, United States.
How many employees does BioCardia have?
BioCardia is in the 11-50 employee band.
How does BioCardia's funding compare to other Biotechnology startups?
BioCardia's latest round of $4.4M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's BioCardia Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioCardia is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.